Personalis (PSNL) Competitors $6.77 -0.14 (-2.03%) Closing price 04:00 PM EasternExtended Trading$6.77 0.00 (-0.06%) As of 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PSNL vs. PACS, LFST, NHC, ARDT, PGNY, AVAH, GRAL, VRDN, TDOC, and OMDAShould you be buying Personalis stock or one of its competitors? The main competitors of Personalis include PACS Group (PACS), LifeStance Health Group (LFST), National HealthCare (NHC), Ardent Health (ARDT), Progyny (PGNY), Aveanna Healthcare (AVAH), GRAIL (GRAL), Viridian Therapeutics (VRDN), Teladoc Health (TDOC), and Omada Health (OMDA). These companies are all part of the "healthcare" industry. Personalis vs. Its Competitors PACS Group LifeStance Health Group National HealthCare Ardent Health Progyny Aveanna Healthcare GRAIL Viridian Therapeutics Teladoc Health Omada Health Personalis (NASDAQ:PSNL) and PACS Group (NYSE:PACS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability. Does the media favor PSNL or PACS? In the previous week, PACS Group had 4 more articles in the media than Personalis. MarketBeat recorded 4 mentions for PACS Group and 0 mentions for Personalis. PACS Group's average media sentiment score of 0.82 beat Personalis' score of 0.00 indicating that PACS Group is being referred to more favorably in the news media. Company Overall Sentiment Personalis Neutral PACS Group Positive Which has more volatility & risk, PSNL or PACS? Personalis has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Comparatively, PACS Group has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Which has stronger valuation and earnings, PSNL or PACS? PACS Group has higher revenue and earnings than Personalis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPersonalis$84.61M7.10-$81.28M-$1.28-5.29PACS Group$3.11B0.69$112.87MN/AN/A Is PSNL or PACS more profitable? PACS Group has a net margin of 0.00% compared to Personalis' net margin of -113.70%. PACS Group's return on equity of 0.00% beat Personalis' return on equity.Company Net Margins Return on Equity Return on Assets Personalis-113.70% -47.57% -35.05% PACS Group N/A N/A N/A Do analysts recommend PSNL or PACS? Personalis currently has a consensus target price of $7.42, suggesting a potential upside of 9.55%. PACS Group has a consensus target price of $31.00, suggesting a potential upside of 119.86%. Given PACS Group's higher probable upside, analysts plainly believe PACS Group is more favorable than Personalis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Personalis 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00PACS Group 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Do institutionals and insiders have more ownership in PSNL or PACS? 61.9% of Personalis shares are held by institutional investors. 3.8% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryPACS Group beats Personalis on 8 of the 14 factors compared between the two stocks. Get Personalis News Delivered to You Automatically Sign up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PSNL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PSNL vs. The Competition Export to ExcelMetricPersonalisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$600.36M$4.46B$6.02B$10.57BDividend YieldN/A1.44%5.92%4.70%P/E Ratio-5.2910.9176.4726.49Price / Sales7.1021.61582.87128.74Price / CashN/A7.0138.1961.33Price / Book2.364.0312.546.48Net Income-$81.28M-$134.23M$3.30B$277.02M7 Day Performance13.21%7.47%28,086.98%1.84%1 Month Performance40.75%9.96%30,478.96%8.29%1 Year Performance40.46%54.18%35,729.70%36.66% Personalis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PSNLPersonalis3.3571 of 5 stars$6.77-2.0%$7.42+9.6%+40.2%$600.36M$84.61M-5.29400PACSPACS Group3.2242 of 5 stars$13.84-1.0%$31.00+124.1%-63.9%$2.13B$3.11B0.0032,433LFSTLifeStance Health Group2.9621 of 5 stars$5.42flat$8.50+56.8%-20.9%$2.11B$1.32B-108.4010,218NHCNational HealthCareN/A$122.47-3.1%N/A+1.2%$1.96B$1.46B15.3512,400ARDTArdent Health3.9132 of 5 stars$13.23-0.2%$19.33+46.1%-30.7%$1.90B$5.97B7.3124,900Positive NewsPGNYProgyny3.9944 of 5 stars$21.42-0.2%$25.44+18.8%+31.1%$1.85B$1.17B36.31310AVAHAveanna Healthcare1.1538 of 5 stars$8.87+1.4%$7.92-10.7%+81.0%$1.83B$2.02B110.8833,500GRALGRAIL1.0763 of 5 stars$58.77+17.9%$31.50-46.4%+368.4%$1.80B$125.60M-4.481,360High Trading VolumeVRDNViridian Therapeutics2.0716 of 5 stars$21.61+7.0%$34.88+61.4%-9.9%$1.65B$300K-5.6450Positive NewsTDOCTeladoc Health2.142 of 5 stars$8.22+0.7%$9.80+19.3%-12.1%$1.44B$2.57B-6.905,500OMDAOmada HealthN/A$22.32-2.0%$24.50+9.8%N/A$1.31BN/A0.00849News CoveragePositive News Related Companies and Tools Related Companies PACS Competitors LFST Competitors NHC Competitors ARDT Competitors PGNY Competitors AVAH Competitors GRAL Competitors VRDN Competitors TDOC Competitors OMDA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PSNL) was last updated on 10/2/2025 by MarketBeat.com Staff From Our PartnersThis Biotech has a clinical approach that intrigues investorsThis biotech is gearing up for Phase 2 trials with a strategy to unlock multiple approvals from one study. ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredAmerica’s Lost StocksPorter Stansberry says the real fortunes aren’t in Tesla, Amazon, or AI — but in a handful of overlooked “lost...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Personalis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Personalis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
